We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
189 result(s) found, displaying 11 to 20
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for KISUNLA donanemab 350 mg/20 mL concentrated solution for intravenous infusion vial.
-
Prescription medicine registrationActive ingredients: mirikizumab.
-
Australian public assessment report (AusPar)Kisunla (donanemab) has been approved for the treatment of patients with mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s dementia (early symptomatic Alzheimer’s disease) that have only one or no copies of the apolipoprotein E ε4 (ApoE ε4) gene.
-
Prescription medicine registrationActive ingredients: tirzepatide.
-
Prescription medicine registrationActive ingredients: donanemab.
-
Cancellation by sponsorRequested by Eli Lilly Australia Pty Ltd
-
Cancellation by sponsorRequested by Eli Lilly Australia Pty Ltd
-
Cancellation by sponsorRequested by Eli Lilly Australia Pty Ltd
-
Cancellation by sponsorRequested by Eli Lilly Australia Pty Ltd
-
Cancellation by sponsorRequested by Eli Lilly Australia Pty Ltd